Tolerability and antitumor activity of cemiplimab, a human monoclonal anti–PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort

1. Moreno, V.
2. Garrido, P.
3. Papadopoulos, K.P.
4. De Miguel Luken, M.J.
5. Gil-Martin, M.
6. Aljumaily, R.
7. Rosen, L.S.
8. Rietschel, P.
9. Mohan, K.K.
10. Yoo, S.-Y.
11. Stankevich, E.
12. Lowy, I.
13. Fury, M.G.